BioStock: Status Report Cereno Scientific – Expanded potential in cardiovascular disease
Cardiovascular disease is the number one killer in the world, and better treatments are in high demand. Swedish biotech company Cereno Scientific is developing new treatments for both common and rare cardiovascular diseases and will initiate a phase II trial with lead candidate CS1 in September this year. During 2021, the company has also strengthened the team, their IP and expanded their portfolio with two development programmes in close collaboration with the University of Michigan. BioStock has now published a status report that can be downloaded at biostock.se.
Read the status report on Cereno Scientific at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/